Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc (CNTA): 8 pipeline candidates · 1 upcoming catalyst · ~12 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
12.0 months
D/E 0.32 · 0% dilution
Lead: Phase 2/Phase 3
8 candidates
1 upcoming, next in ~561d
0 buys · 10 sells (180d)
A transparent, data-derived signal for Centessa Pharmaceuticals plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.2B
Cash
$63.1M
Quarterly Burn
$72.2M
Runway
12.0 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| cleminorexton | Phase 2/Phase 3 |
| LB101 | Phase 1 |
| lockbody platform products | Preclinical |
| LockBody technology platform | N/A |
| ORX142 | Phase 1 |
| ORX489 | Phase 1 |
| ORX750 | Phase 2 |
| SerpinPC | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$4.21B
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 10,517,806 | $417.8M |
| adage capital partners gp, l.l.c. | 8,925,010 | $354.5M |
| pentwater capital management lp | 8,170,000 | $324.5M |
| janus henderson group plc | 6,985,954 | $277.5M |
| fmr llc | 6,852,047 | $272.2M |
| farallon capital management llc | 4,809,000 | $191.0M |
| tcg crossover management, llc | 4,286,480 | $170.3M |
| morgan stanley | 4,268,353 | $169.5M |
| paradigm biocapital advisors lp | 3,574,048 | $142.0M |
| deep track capital, lp | 3,158,041 | $125.4M |
Showing top 10 of 156 institutional holders of Centessa Pharmaceuticals plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Centessa Pharmaceuticals plc's pipeline?
Centessa Pharmaceuticals plc (CNTA) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Centessa Pharmaceuticals plc's lead drug candidate?
Centessa Pharmaceuticals plc's most advanced tracked candidate is cleminorexton (Phase 2/Phase 3) for Narcolepsy Type 1.
What is Centessa Pharmaceuticals plc's next catalyst?
Centessa Pharmaceuticals plc's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerab" — expected December 31, 2027.
What is Centessa Pharmaceuticals plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Centessa Pharmaceuticals plc has approximately 12.0 months of cash runway.
What is Centessa Pharmaceuticals plc's market capitalization?
Centessa Pharmaceuticals plc's market capitalization is approximately $6.2B.
Get the full picture on Centessa Pharmaceuticals plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.